Search Results

Displaying Results 1-2 of 2 "'ACST'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

Apr 28, 2025, 07:00 ET ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

antibody drug conjugates (ADCs) targeting Claudin-6 (CLDN6), prostate-specific membrane antigen (PSMA), and Alanine, Serine, Cysteine Transporter 2 (ACST2) as presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.

More news about: ADC Therapeutics SA

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Mar 25, 2025, 17:30 ET ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

"We are excited to present preclinical data on our exatecan-based Claudin-6, PSMA, and ACST2-targeting antibody-drug conjugates," said Patrick van Berkel, PhD, Chief Scientific Officer of ADC Therapeutics. "These

More news about: ADC Therapeutics SA

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.